Cell/Gene Tx channel feed

Ex­cite­ment over sick­le cell now shifts to long slog of de­liv­er­ing treat­ments, in piv­otal year for blue­bird and gene ther­a­py

Last year
Pharma

Ed­i­tas Med­i­cine pads run­way with $50M up­front from Ver­tex for Cas9 li­cense

Last year
Deals

MIT gene edit­ing spin­out launch­es with $213M to write the 'fi­nal chap­ter in ge­nom­ic med­i­cine'

Last year
Financing
Startups

Ex­clu­sive: Shi­no­bi rais­es $51M to take on cell ther­a­py chal­lenges with ex-Wu­gen CEO at helm, Carl June in sup­port

Last year
Financing
Startups

Biotech CAR-T roundup: Au­to­lus, Gra­cell tout ear­ly-stage da­ta at #ASH23

Last year
R&D

Graphite founder takes drug to re­cent­ly-launched Ka­mau Ther­a­peu­tics for a sec­ond chance: #ASH23

Last year
Startups

Au­toim­mune pa­tients in CAR-T study see strik­ing im­prove­ments across lu­pus and oth­er dis­eases

Last year
R&D

Roche part­ner touts ear­ly al­lo­gene­ic CAR-T da­ta at #ASH23, but dura­bil­i­ty re­mains key ques­tion

Last year
R&D

Ar­cel­lx, Kite aim to keep chip­ping away at Carvyk­ti ad­van­tage with new mul­ti­ple myelo­ma da­ta: #ASH23

Last year
R&D

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win re­view vouch­er

Last year
Pharma

How one lab's decades­long search for the 'holy grail' of sick­le cell led to the first CRISPR ther­a­py

Last year
R&D
In Focus

Af­ter ink­ing re­verse merg­er, Graphite Bio di­vests gene edit­ing pipeline to new­ly-formed biotech

Last year
Startups
R&D

Cel­lec­tis shifts CAR-T man­u­fac­tur­ing in-house, boosts ef­fi­ca­cy com­pared to third-par­ty CD­MOs: #ASH23 

Last year
Manufacturing

Sen. Bill Cas­sidy plots a path for more com­mer­cial­ly vi­able cell and gene ther­a­pies

Last year
Pharma

A CAR-T ther­a­py in­vent­ed at Seat­tle Chil­dren’s was nev­er ap­proved for kids. Now the hos­pi­tal is launch­ing its own pe­di­atric CAR-T start­up

Last year
Startups

CRISPR repri­or­i­tizes CAR-T pipeline with cuts, ex­pands in­to au­toim­mune dis­ease as US de­ci­sion for exa-cel looms

Last year
R&D

At­se­na touts one-year da­ta for con­gen­i­tal eye dis­ease ther­a­py as it seeks part­ner for piv­otal study

Last year
R&D

Or­na Ther­a­peu­tics trims staff in ‘de­fen­sive re­duc­tion’ de­spite large fi­nanc­ing hauls

Last year
People
Startups

Clin­i­cians say ben­e­fits of CAR-T con­tin­ue to out­weigh risk of T-cell ma­lig­nan­cies

Last year
Pharma
FDA+

Gilead­'s cell ther­a­py busi­ness Kite cuts 7% of work­force

Last year
People

Gen­er­a­tion Bio to lay off 68 em­ploy­ees in a dif­fi­cult year for non-vi­ral gene ther­a­py biotechs

Last year
People

FDA opens re­view of CAR-T safe­ty af­ter iden­ti­fy­ing 19 cas­es of post-treat­ment blood can­cer

Last year
Pharma
FDA+

Bio­Marin lands three-year deal for Ger­man cov­er­age of gene ther­a­py at $900K per pa­tient

Last year
Pharma

RoslinCT to com­mer­cial­ly man­u­fac­ture CRISPR-edit­ed ther­a­py Cas­gevy af­ter col­lab ex­ten­sion with Ver­tex, CRISPR

Last year
Manufacturing
First page Previous page 11121314151617 Next page Last page
A service from the Financial Times